Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (4): 24-30.doi: 10.6040/j.issn.1671-7554.0.2024.0184

• Clinical Medicine • Previous Articles    

Subcellular localization pattern of bromodomain containing 9 in colorectal cancer and its clinical significance

LIU Chuncheng1, LIU Xiaohan1, WEI Yanruoxue1, LI Ziqi1, LIU Yukun1,2, ZHAO Ran1,2   

  1. 1. Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. Department of Pathology, Affiliated Hospital of Jining Medical University, Jining 272029, Shandong, China
  • Published:2024-05-16

PDF (PC)

57

Abstract: Objective To investigate the protein expression level, subcellular localization pattern and clinical significance of bromodomain containing 9(BRD9)in colorectal cancer(CRC). Methods Surgical resection specimens of CRC were collected, and immunohistochemistry(EnVision method)was used to detect BRD9 protein expression and subcellular localization. The relationship between BRD9 expression and clinicopathological features and prognosis of CRC patients was analyzed. Results Among 508 CRC tissue specimens, BRD9 was overexpressed in 71.46%(363/508)of patients, and 80.31%(408/508)of patients showed nuclear positive staining in immunohistochemistry for BRD9. The expression of BRD9 was correlated with tumor size(P=0.025), lymph node metastasis(P=0.004), nerve invasion(P=0.043), differentiation grade(P=0.017)and TNM stage(P=0.002). The subcellular localization of BRD9 was correlated with lymph node metastasis(P=0.040)and TNM stage(P=0.026). The difference was statistically significant. Meanwhile, BRD9 high expression served as an independent poor prognostic factor(HR=1.994, P=0.002). More important, in patients with BRD9 low expression, cytoplasmic BRD9 expression was an independent poor prognostic factor of patients(HR=8.056, P=0.001). Conclusion The subcellular localization of BRD9 is heterogeneous in CRC patients. The high expression and cytoplasmic localization of BRD9 are related to the occurrence and development of CRC, and could be used as an independent predictor for the prognosis of CRC patients.

Key words: Colorectal cancer, Immunohistochemistry, Bromodomain containing 9, Subcellular localization, Prognosis

CLC Number: 

  • R735.3
[1] Morgan E, Arnold M, Gini A,et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN [J]. Gut, 2023, 72(2):338-344.
[2] Li N, Lu B, Luo C, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America [J].Cancer Lett,2021, 522: 255-268.doi: 10.1016/j.canlet.2021.09.034.
[3] Mauri G, Sartore-Bianchi A, Russo AG, et al. Early-onset colorectal cancer in young individuals [J]. Mol Oncol, 2019, 13(2): 109-131.
[4] Ali MM, Naz S, Ashraf S, et al. Epigenetic modulation by targeting bromodomain containing protein 9(BRD9): Its therapeutic potential and selective inhibition [J]. Int J Biol Macromol, 2023, 230: 123428. doi: 10.1016/j.ijbiomac.2023.123428.
[5] Chen P, Du R, Chang Z, et al. Bromodomain-containing protein 9 activates proliferation and epithelial-mesenchymal transition of colorectal cancer via the estrogen pathway in vivo and in vitro [J]. J Gastrointest Oncol,2023, 14(2): 980-996.
[6] Zhao R, Liu Y, Wu C, et al. BRD7 promotes cell proliferation and tumor growth through stabilization of c-Myc in colorectal cancer [J]. Front Cell Dev Biol, 2021, 9: 659392. doi: 10.3389/fcell.2021.659392.
[7] Liu Y, Zhao R, Wei Y, et al. BRD7 expression and c-Myc activation forms a double-negative feedback loop that controls the cell proliferation and tumor growth of nasopharyngeal carcinoma by targeting oncogenic miR-141 [J]. J Exp Clin Cancer Res, 2018, 37(1): 64. doi: 10.1186/s13046-018-0734-2.
[8] Chen Y, Gao Z, Mohd-Ibrahim I, et al. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours [J]. Clin Transl Med, 2024, 14(2): e1543. doi: 10.1002/ctm2.1543.
[9] Ahmed NS, Gatchalian J, Ho J, et al. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4 [J]. Proc Natl Acad Sci U S A, 2022, 119(1): e2110812119. doi: 10.1073/pnas.2110812119.
[10] Kurata K, Samur MK, Liow P, et al. BRD9 degradation disrupts ribosome biogenesis in multiple myeloma [J]. Clin Cancer Res, 2023, 29(9): 1807-1821.
[11] Alpsoy A, Utturkar SM, Carter BC, et al. BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression [J]. Cancer Res, 2021, 81(4): 820-833.
[12] Liu T, Li Q, Jin Q, et al. Targeting HMGB1: A potential therapeutic strategy for chronic kidney disease [J]. Int J Biol Sci, 2023, 19(15): 5020-5035.
[13] Hao SH, Ma XD, Xu L, et al. Dual specific phosphatase 4 suppresses ferroptotosis and enhances sorafenib resistance in hepatocellular carcinoma [J]. Drug Resist Updat, 2024, 73: 101052. doi: 10.1016/j.drup.2024.101052.
[14] Crodian JS, Weldon BM, Tseng YC, et al. Nuclear trafficking dynamics of Bromodomain-containing protein 7(BRD7), a switch/sucrose non-fermentable(SWI/SNF)chromatin remodelling complex subunit, in porcine oocytes and cleavage-stage embryos [J]. Reprod Fertil Dev, 2019, 31(9): 1497-1506.
[15] Vivenza D, Garrone O, Brizio R, et al. Expression and subcellular localization of the bromodomain-containing protein 7 is a prognostic biomarker in breast cancer [J]. Anticancer Drugs, 2020, 31(4): 423-430.
[16] Dariya B, Aliya S, Merchant N, et al. Colorectal cancer biology, diagnosis, and therapeutic approaches [J]. Crit Rev Oncog, 2020, 25(2): 71-94.
[17] Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer [J]. Int J Mol Sci, 2022, 23(2): 852. doi: 10.3390/ijms23020852.
[18] Chen H, Zhai C, Xu X, et al. Multilevel heterogeneity of colorectal cancer liver metastasis [J]. Cancers(Basel), 2023, 16(1): 59. doi: 10.3390/cancers16010059.
[19] Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer [J]. Nat Rev Clin Oncol, 2017, 14(4): 235-246.
[20] Saoudi González N, Salvà F, Ros J, et al. Unravelling the complexity of colorectal cancer: heterogeneity, clonal evolution, and clinical implications [J]. Cancers(Basel),2023,15(16): 4020. doi: 10.3390/cancers15164020.
[21] Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis [J]. Gastroenterology, 2020, 158(2): 291-302.
[22] Hong SN. Genetic and epigenetic alterations of colorectal cancer [J]. Intest Res, 2018, 16(3): 327-337.
[23] Singh MP, Rai S, Suyal S, et al. Genetic and epigenetic markers in colorectal cancer screening: recent advances [J]. Expert Rev Mol Diagn, 2017, 17(7): 665-685.
[24] Pan Z, Zhao Y, Wang X, et al. Targeting bromodomain-containing proteins: research advances of drug discovery [J]. Mol Biomed, 2023, 4(1): 13. doi: 10.1186/s43556-023-00127-1.
[25] Marmorstein R, Zhou MM. Writers and readers of histone acetylation: structure, mechanism, and inhibition [J]. Cold Spring Harb Perspect Biol, 2014, 6(7): a018762. doi: 10.1101/cshperspect.a018762.
[26] Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer [J]. Nat Rev Mol Cell Biol, 2017, 18(4): 246-262.
[1] YANG Xueyan, WU Yinping, LYU Li, ZHAO Zehua, MA Hangyu, LI Fengcai, WANG Kai, FAN Yuchen. Diagnostic value of dynamic changes of monocyte-to-lymphocyte ratio in acute-on-chronic hepatitis B liver failure [J]. Journal of Shandong University (Health Sciences), 2024, 62(3): 61-69.
[2] DIAO Yujie, LIN Lin, LI Wenxuan, WANG Zhouyang, JIANG Bei, HU Yingying, LIU Guangyi. Neutrophil-to-platelet ratio predicts adverse renal outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis and its synergistic multifactor optimization model [J]. Journal of Shandong University (Health Sciences), 2024, 62(2): 60-68.
[3] JING Kai, XU Zhiwei, LI Leping. Exploring colorectal cancer related genes and their functions based on GEO [J]. Journal of Shandong University (Health Sciences), 2024, 62(1): 21-30.
[4] DONG Yaqi, WANG Xinhui, ZHAO Yinghui, WANG Chuanxin. Clinical value of serum exosomal LINC02163 as a marker for distant metastasis of colorectal cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(9): 19-28.
[5] FAN Rong, LI Binbin, MA Xiaoli, WANG Yunshan, JIA Yanfei. Expressions and clinical significance of DEC2 and HIF-2α in gastric cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(7): 12-18.
[6] LIU Yan, LENG Shanshan, XIA Xiaona, DONG Hao, HUANG Chencui, MENG Xiangshui. Functional outcomes of 376 patients with supratentorial spontaneous intracerebral hemorrhage based on radiomic parameters [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 59-67.
[7] CHEN Rong, YANG Yue, YANG Zhixiang, SU Yaying, PANG Zhiying, WANG Dawei, CUI Shujun, YANG Fei. Texture analysis based on CT to predict the short-term outcomes of acute pulmonary embolism [J]. Journal of Shandong University (Health Sciences), 2023, 61(12): 78-85.
[8] HUA Yuefan, HE Keyao, ZHANG Jiahao, QIAN Mengfan, LIU Yiwen, KONG Jinyu, YANG Haijun, ZHOU Fuyou. Effects of high expressions of hypoxia inducible factor-1 and vascular endothelial growth factor induced by Fusobacterium nucleatum on survival and prognosis of patients with esophageal squamous cell carcinoma [J]. Journal of Shandong University (Health Sciences), 2023, 61(11): 59-67.
[9] ZHAO Qidi, WANG Kai, ZHAO Xiaogang, YAN Tao, WANG Yadong, DU Jiajun. Constructing and validating a prognostic model for patients with stage IIIB non-small cell lung cancer based on SEER database [J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 23-37.
[10] ZHENG Su, CHEN Shuhua, LI Hua, DENG Jie, CHEN Chunhong, WANG Xiaohui, FENG Weixing, HAN Xiaodi, ZHANG Yujia, LI Na, LI Mo, FANG Fang. Correlation between EEG variations and BASED evaluation of the efficacy of ACTH treatment in 54 cases of infantile spasms [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 91-96.
[11] WANG Lihui, GAO Min, KONG Beihua. Angiosarcoma of the uterus: a report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 108-112.
[12] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[13] ZHANG Yufeng, XU Min, XING Xiuli, PANG Shuguang, HU Keqing. Epidemiological characteristics of 689 patients with non-ST-segment elevation myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 118-122.
[14] LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58.
[15] KONG Linxiaoyu, SUN Shuzhen, YU Lichun, JIA Mengwen. Analysis of 5-year survival rate and prognosis in 188 children with systemic lupus erythematosus [J]. Journal of Shandong University (Health Sciences), 2022, 60(12): 69-76.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd